GL Capital-led group to buy SciClone Pharma for $605 mln

A group of investors led by GL Capital have agreed to buy SciClone Pharmaceuticals Inc in a deal valued at about $605 million. The buyer consortium includes Bank of China Group Investment Ltd, CDH Investments, Ascendent Capital Partners and Boying. SciClone is a specialty pharmaceutical company with a product portfolio in oncology, infectious diseases and cardiovascular disorders.

DealsNorth AmericaUSBriefs